[1]. Effect of Butyrate-Producing Enterobacteria and Proton Pump Inhibitors on Advanced Hepatocellular Carcinoma Treatment With Durvalumab and Tremelimumab
（2026年） [査読] 有
[2]. Validation study of age-independent fibrosis score (Fibrosis-3 index) in patients with metabolic dysfunction-associated steatotic liver disease
HEPATOLOGY RESEARCH （2024年） [査読] 有
[3]. A genome-wide association study identified PTPN2 as a population-specific susceptibility gene locus for primary biliary cholangitis
HEPATOLOGY （2024年） [査読] 有
[4]. Hepatic inflammation and fibrosis are profiles related to mid-term mortality in biopsy-proven MASLD: A multicenter study in Japan
Alimentary Pharmacology & Therapeutics （2024年） [査読] 有
[5]. Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma
Cancer reports (Hoboken, N.J.) （2024年） [査読] 有
[6]. Association of PPI and antibiotics with the clinical outcomes of HCC patients receiving atezolizumab and bevacizumab: A multicenter analysis.
Hepatology research : the official journal of the Japan Society of Hepatology （2023年） [査読] 有
[DOI] [7]. Breach of tolerance versus burden of bile acids: Resolving the conundrum in the immunopathogenesis and natural history of primary biliary cholangitis.
Journal of autoimmunity [巻]136 [頁]103027 （2023年） [査読] 有
[DOI] [8]. Diagnostic accuracy of enhanced liver fibrosis test for nonalcoholic steatohepatitis-related fibrosis: Multicenter study.
Hepatology research : the official journal of the Japan Society of Hepatology [巻]53 [号]4 [頁]312 -321 （2023年） [査読] 有
[DOI] [9]. Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients.
Journal of cancer research and clinical oncology （2023年） [査読] 有
[DOI] [10]. Rifaximin Improves Liver Functional Reserve by Regulating Systemic Inflammation.
Journal of clinical medicine [巻]12 [号]6 （2023年） [査読] 有
[DOI] [11]. Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non-viral infection: A Japanese multicenter observational study.
Cancer medicine [巻]12 [号]5 [頁]5293 -5303 （2023年） [査読] 有
[DOI] [12]. Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?
Targeted oncology [巻]18 [号]2 [頁]221 -233 （2023年） [査読] 有
[DOI] [13]. New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study.
Cancer medicine [巻]12 [号]6 [頁]6980 -6993 （2023年） [査読] 有
[DOI] [14]. Validation of the utility of Agile scores to identify advanced fibrosis and cirrhosis in Japanese patients with nonalcoholic fatty liver disease.
Hepatology research : the official journal of the Japan Society of Hepatology （2023年） [査読] 有
[DOI] [15]. Noninvasive tests predict liver-related events and mortality in patients with nonalcoholic fatty liver disease: sub-analysis of the CLIONE-Asia study.
Journal of gastroenterology and hepatology （2023年） [査読] 有
[DOI] [16]. Risk factors for portopulmonary hypertension in patients with cirrhosis: a prospective, multicenter study.
Hepatology international [巻]17 [号]1 [頁]139 -149 （2023年） [査読] 有
[DOI] [17]. The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC-GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis.
Cancer medicine [巻]12 [号]4 [頁]4259 -4269 （2023年） [査読] 有
[DOI] [18]. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population.
European journal of cancer (Oxford, England : 1990) [巻]180 [頁]9 -20 （2023年） [査読] 有
[DOI] [19]. Multicenter, retrospective, cohort study shows platelet counts predict hepatocellular carcinoma development in patients with nonalcoholic fatty liver disease.
Hepatology research : the official journal of the Japan Society of Hepatology （2023年） [査読] 有
[DOI] [20]. Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Oncology （2023年） [査読] 有
[DOI] [21]. Nutritional Status Is Associated with Prognosis in Patients with Advanced Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.
Oncology [巻]101 [号]4 [頁]270 -282 （2023年） [査読] 有
[DOI] [22]. Clinical outcomes of antithrombin III-based therapy for patients with portal vein thrombosis: A retrospective, multicenter study.
Hepatology research [巻]53 [号]1 [頁]51 -60 （2023年） [査読] 有
[DOI] [23]. Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib.
Cancer medicine [巻]12 [号]1 [頁]325 -334 （2023年） [査読] 有
[DOI] [24]. Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Cancer medicine （2022年） [査読] 有
[DOI] [25]. Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study.
Journal of cancer research and clinical oncology （2022年） [査読] 有
[DOI] [26]. Age-dependent effects of diabetes and obesity on liver-related events in non-alcoholic fatty liver disease: Subanalysis of CLIONE in Asia.
Journal of gastroenterology and hepatology [巻]37 [号]12 [頁]2313 -2320 （2022年） [査読] 有
[DOI] [27]. Arg-Gly-Asp-binding integrins activate hepatic stellate cells via the hippo signaling pathway.
Cellular signalling [巻]99 [頁]110437 （2022年） [査読] 有
[DOI] [28]. Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis.
Cancer medicine [巻]11 [号]20 [頁]3796 -3808 （2022年） [査読] 有
[DOI] [29]. Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study.
Hepatology international [巻]16 [号]5 [頁]1150 -1160 （2022年） [査読] 有
[DOI] [30]. A Case of Hepatic Angiosarcoma with Peliosis Hepatis.
Internal medicine (Tokyo, Japan) （2022年） [査読] 有
[DOI] [31]. Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice.
Hepatology research : the official journal of the Japan Society of Hepatology [巻]52 [号]9 [頁]773 -783 （2022年） [査読] 有
[DOI] [32]. Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysis.
European journal of gastroenterology & hepatology [巻]34 [号]8 [頁]857 -864 （2022年） [査読] 有
[DOI] [33]. C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib.
Scientific reports [巻]12 [号]1 [頁]8421 （2022年） [査読] 有
[DOI] [34]. Mac-2-binding protein glycan isomer predicts all malignancies after sustained virological response in chronic hepatitis C.
Hepatology communications （2022年） [査読] 有
[DOI] [35]. Time-course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis.
Hepatology research [巻]52 [号]3 [頁]235 -246 （2022年） [査読] 有
[DOI] [36]. Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria - Multicenter analysis.
Hepatology research [巻]52 [号]3 [頁]308 -316 （2022年） [査読] 有
[DOI] [37]. Neutrophil-lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis.
European journal of gastroenterology & hepatology （2022年） [査読] 有
[DOI] [38]. Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis.
Hepatology research （2022年） [査読] 有
[DOI] [39]. Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-based Cohort Study.
Clinical gastroenterology and hepatology （2022年） [査読] 有
[DOI] [40]. Clinical Predictor of Urinary Protein as Adverse Event Associated with Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma.
Oncology [巻]100 [号]12 [頁]645 -654 （2022年） [査読] 有
[DOI] [41]. Environmental factors, medical and family history, and comorbidities associated with primary biliary cholangitis in Japan: a multicenter case-control study.
Journal of gastroenterology [巻]57 [号]1 [頁]19 -29 （2022年） [査読] 有
[DOI] [42]. Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib.
ESMO open [巻]6 [号]6 [頁]100330 （2021年） [査読] 有
[DOI] [43]. Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib.
Liver international [巻]41 [号]12 [頁]2997 -3008 （2021年） [査読] 有
[DOI] [44]. 治療の機会に恵まれずに経過したC型慢性肝炎が，非代償性肝硬変にまで進展したのちにC型肝炎ウイルスの自然排除に至った1例.
肝臓 [巻]62 [号]9 [頁]555 -560 （2021年） [査読] 有
[45]. Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study.
Scientific reports [巻]11 [号]1 [頁]16663 （2021年） [査読] 有
[DOI] [46]. Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma.
ESMO open [巻]6 [号]4 [頁]100190 （2021年） [査読] 有
[DOI] [47]. Azathioprine-induced severe myelosuppression accompanied by massive hair loss and painful oral ulcer in an autoimmune hepatitis patient with minor variant: A case report.
Clinical case reports [巻]9 [号]8 [頁]e04696 （2021年） [査読] 有
[DOI] [48]. Impact of modified albumin-bilirubin grade on survival in patients with HCC who received lenvatinib.
Scientific reports [巻]11 [号]1 [頁]14474 （2021年） [査読] 有
[DOI] [49]. Dilated main pancreatic duct can be a negative predictor of pancreatitis related to biliary SEMS insertion across the papilla.
Scandinavian journal of gastroenterology [巻]56 [号]7 [頁]865 -869 （2021年） [査読] 有
[DOI] [50]. Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis.
Oncology [巻]27 [頁]1 -10 （2021年） [査読] 有
[DOI] [51]. Therapeutic efficacy of lenvatinib as third line treatment following regorafenib for unresectable hepatocellular carcinoma progression.
Hepatology research [巻]51 [号]8 [頁]880 -889 （2021年） [査読] 有
[DOI] [52]. Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma.
Gastroenterology report [巻]9 [号]2 [頁]133 -138 （2021年） [査読] 有
[DOI] [53]. What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?
Liver cancer [巻]10 [号]2 [頁]115 -125 （2021年） [査読] 有
[DOI] [54]. Ursodeoxycholic acid impairs liver-infiltrating T-cell chemotaxis through IFN-γ and CX3CL1 production in primary biliary cholangitis.
European journal of immunology [巻]51 [号]6 [頁]1519 -1530 （2021年） [査読] 有
[DOI] [55]. Giant Hepatomegaly with Spleno-testicular Enlargement in a Patient with Apolipoprotein A-I Amyloidosis: An Uncommon Type of Amyloidosis in Japan.
Internal medicine [巻]60 [号]4 [頁]575 -581 （2021年） [査読] 有
[DOI] [56]. Platelet-lymphocyte ratio predicts survival in patients with hepatocellular carcinoma who receive lenvatinib: an inverse probability weighting analysis.
European journal of gastroenterology & hepatology [巻]32 [号]2 [頁]261 -268 （2021年） [査読] 有
[DOI] [57]. The ursodeoxycholic acid response score predicts pathological features in primary biliary cholangitis.
Hepatology research [巻]51 [号]1 [頁]80 -89 （2021年） [査読] 有
[DOI] [58]. Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study.
Infectious diseases and therapy [巻]9 [号]4 [頁]851 -866 （2020年） [査読] 有
[DOI] [59]. Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting.
Journal of gastroenterology and hepatology （2020年） [査読] 有
[DOI] [60]. A validation study of the Ursodeoxycholic Acid Response Score in Japanese patients with primary biliary cholangitis.
Liver international [巻]40 [号]8 [頁]1926 -1933 （2020年） [査読] 有
[DOI] [61]. Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone?
International journal of molecular sciences [巻]21 [号]14 （2020年） [査読] 有
[DOI] [62]. Neutrophil-to-lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib.
Liver international [巻]40 [号]4 [頁]968 -976 （2020年） [査読] 有
[DOI] [63]. Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma.
Oncology [巻]98 [号]5 [頁]295 -302 （2020年） [査読] 有
[DOI] [64]. Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis.
Hepatology [巻]70 [号]6 [頁]2035 -2046 （2019年） [査読] 有
[DOI] [65]. Clinical characteristics and risk factors for stent-stone complex formation following biliary plastic stent placement in patients with common bile duct stones.
Journal of hepato-biliary-pancreatic sciences [巻]25 [号]10 [頁]448 -454 （2018年）
[DOI] [66]. Emergence of anti-mitochondrial M2 antibody in patient with angioimmunoblastic T-cell lymphoma.
Clinical journal of gastroenterology [巻]11 [号]4 [頁]302 -308 （2018年）
[DOI] [67]. Rapid Changes in Serum Lipid Profiles during Combination Therapy with Daclatasvir and Asunaprevir in Patients Infected with Hepatitis C Virus Genotype 1b.
Gut and liver [巻]12 [号]2 [頁]201 -207 （2018年）
[DOI] [68]. A case of a primary hepatic so-called adenosarcoma with heterotopic ossification: possibly of biliary adenofibroma origin.
Human pathology [巻]73 [頁]108 -113 （2018年）
[DOI] [69]. Critical role of CREBH-mediated induction of transforming growth factor β2 by hepatitis C virus infection in fibrogenic responses in hepatic stellate cells.
Hepatology (Baltimore, Md.) [巻]66 [号]5 [頁]1430 -1443 （2017年）
[DOI] [70]. Successful Interferon Therapy Reverses Enhanced Hepatic Progenitor Cell Activation in Patients with Chronic Hepatitis C.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research [巻]35 [号]12 [頁]956 -62 （2015年）
[DOI] [71]. Long-term pegylated interferon monotherapy following 72 weeks of pegylated interferon and ribavirin in hepatitis C virus genotype-1-infected slow responders.
Internal medicine (Tokyo, Japan) [巻]54 [号]3 [頁]273 -9 （2015年）
[DOI] [72]. Does hepatic oxidative stress enhance activation of nuclear factor-E2-related factor in patients with nonalcoholic steatohepatitis?
Antioxidants & redox signaling [巻]20 [号]3 [頁]538 -43 （2014年）
[DOI] [73]. Improved Serum Alpha-Fetoprotein Levels after Iron Reduction Therapy in HCV Patients.
ISRN hepatology [巻]2014 [頁]875140 （2014年）
[DOI] [74]. Clonality, activated antigen-specific CD8(+) T cells, and development of autoimmune cholangitis in dnTGFβRII mice.
Hepatology (Baltimore, Md.) [巻]58 [号]3 [頁]1094 -104 （2013年）
[DOI] [75]. Differential expression of hepatic apurinic/apyrimidinic endonuclease 1, a DNA repair enzyme, in chronic hepatitis.
World journal of hepatology [巻]5 [号]4 [頁]206 -13 （2013年）
[DOI] [76]. Overexpression of microRNA-21 is associated with elevated pro-inflammatory cytokines in dominant-negative TGF-β receptor type II mouse.
Journal of autoimmunity [巻]41 [頁]111 -9 （2013年）
[DOI] [77]. Deletion of interleukin (IL)-12p35 induces liver fibrosis in dominant-negative TGFβ receptor type II mice.
Hepatology (Baltimore, Md.) [巻]57 [号]2 [頁]806 -16 （2013年）
[DOI] [78]. Identification of potential cytokine pathways for therapeutic intervention in murine primary biliary cirrhosis.
PloS one [巻]8 [号]9 [頁]e74225 （2013年）
[DOI] [79]. Mincle and human B cell function.
Journal of autoimmunity [巻]39 [号]4 [頁]315 -22 （2012年）
[DOI] [80]. The immunophysiology and apoptosis of biliary epithelial cells: primary biliary cirrhosis and primary sclerosing cholangitis.
Clinical reviews in allergy & immunology [巻]43 [号]3 [頁]230 -41 （2012年）
[DOI] [81]. The immunobiology of colitis and cholangitis in interleukin-23p19 and interleukin-17A deleted dominant negative form of transforming growth factor beta receptor type II mice.
Hepatology (Baltimore, Md.) [巻]56 [号]4 [頁]1418 -26 （2012年）
[DOI] [82]. Enhanced hepatic Nrf2 activation after ursodeoxycholic acid treatment in patients with primary biliary cirrhosis.
Antioxidants & redox signaling [巻]13 [号]3 [頁]259 -68 （2010年）
[DOI] [83]. [Spontaneous regression of pancreatic arteriovenous malformation under the influence of severe acute pancreatitis: a case report].
Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology [巻]114 [号]11 [頁]2012 -2019
[DOI]